Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.
about
Medical treatment for gastro-entero-pancreatic neuroendocrine tumoursThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsFine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivityLigand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical studySynergistic effect of pasireotide and teriflunomide in carcinoids in vitro.Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPERIlluminating somatostatin analog action at neuroendocrine tumor receptorsPasireotide for the treatment of Cushing's disease.Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implicationsRadiopharmaceutical development of radiolabelled peptides.Radionuclide therapy via SSTR: future aspects from experimental animal studies.Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors.Somatostatin receptor ligands in the treatment of acromegaly.On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitroMolecular basis of agonist docking in a human GPR103 homology model by site-directed mutagenesis and structure-activity relationship studies.Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.Does pasireotide directly modulate skeletal muscle metabolism?Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells.Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths
P2860
Q26751659-CC9361E8-64B6-4E41-B0A6-34ED7DC529BEQ26796357-ADF8C4EE-62E2-4DF7-A5E4-541242C8279BQ26862544-B9E4504A-F4CB-4F81-95C0-87D07D58DF52Q27021274-BDB3A3F5-D766-426F-978C-E26D8AC28E45Q27021347-AC658399-6978-447A-8494-65AACCA6560FQ35001258-5C3ACD41-87D9-4E4B-B972-49C9C8509863Q35216414-6FA38C37-A27F-4E8C-BD60-9F9E477D68EFQ35713096-C28803BC-9E7F-499B-952A-8D14AE3F761DQ36125639-04DA024C-5E2F-4624-87AA-0012A768FB25Q36536629-B5327092-2C17-49F7-9EAA-A78379CD5FBBQ36800401-81E29826-5C8E-4581-9163-6F19EF10E8D6Q37443562-898F4CD1-4BF9-4F92-A6E8-585A83125966Q37763714-E7FA67E3-4430-4AE5-AF8F-244003FD32B2Q37772579-B8D0AE1B-FE06-4394-B245-BE840DE85B38Q37990399-5FE69D2C-E3F5-4964-BA60-C3B5966F1DC0Q38008839-2F2A422F-B708-4694-8FE8-D861F5560B2CQ38132768-D60D6529-CF63-4AA6-A0C4-E49A3513BD2FQ38957573-B6B2E725-5DD4-46F7-B2B8-E6FECA045300Q39125449-8BFC43F5-51A9-48B4-9896-0494258020BEQ39544807-ED07947D-C984-4AC9-9787-1714C631C349Q41548629-FA7DAEC2-452C-448B-91BE-EEFB5E7063CFQ42088341-4074A36C-0CBD-42E2-9A27-0324A5DFC731Q42289652-0EBC2AC0-179A-42F3-9687-4D41125CE510Q47944297-17F479D1-0651-4925-81D4-71DD8039C923Q48307756-8EC638D2-1E58-4C1A-9CFB-0E2901C5CDD9Q51170240-4C1A22F1-090F-4A0D-B737-DAF9781F5A0FQ54144943-64D003CA-D06D-447A-98CC-43B2FA563F4DQ56962802-0E5FE50C-840E-4E43-961A-BFAF92B36FD1
P2860
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Agonist-biased signaling at th ...... e distinct signaling pathways.
@ast
Agonist-biased signaling at th ...... e distinct signaling pathways.
@en
Agonist-biased signaling at th ...... e distinct signaling pathways.
@nl
type
label
Agonist-biased signaling at th ...... e distinct signaling pathways.
@ast
Agonist-biased signaling at th ...... e distinct signaling pathways.
@en
Agonist-biased signaling at th ...... e distinct signaling pathways.
@nl
prefLabel
Agonist-biased signaling at th ...... e distinct signaling pathways.
@ast
Agonist-biased signaling at th ...... e distinct signaling pathways.
@en
Agonist-biased signaling at th ...... e distinct signaling pathways.
@nl
P2093
P2860
P356
P1476
Agonist-biased signaling at th ...... e distinct signaling pathways.
@en
P2093
Agnes Schonbrunn
Beatrice Waser
Helmut R Mäcke
Jean E Rivier
Kimberly A Loesch
Renzo Cescato
P2860
P304
P356
10.1210/ME.2009-0321
P577
2009-11-12T00:00:00Z